Back to Search
Start Over
Improving the analytical toolbox to investigate copurifying host cell proteins presence: N-(4)-(β-acetylglucosaminyl)- l-asparaginase case study
- Source :
- Biotechnology and Bioengineering
- Publication Year :
- 2019
-
Abstract
- Levels of host cell proteins (HCPs) in purification intermediates and drug substances (DS) of monoclonal antibodies (mAbs) must be carefully monitored for the production of safe and efficacious biotherapeutics. During the development of mAb1, an immunoglobulin G1 product, unexpected results generated with HCP Enzyme‐Linked Immunosorbent Assay (ELISA) kit triggered an investigation which led to the identification of a copurifying HCP called N‐(4)‐(β‐acetylglucosaminyl)‐l‐asparaginase (AGA, EC3.5.1.26) by liquid chromatography–tandem mass spectrometry (LC‐MS/MS). The risk assessment performed indicated a low immunogenicity risk for the copurifying HCP and an ad hoc stability study demonstrated no mAb glycan cleavage and thus no impact on product quality. Fractionation studies performed on polishing steps revealed that AGA was coeluted with the mAb. Very interestingly, the native digestion protocol implemented to go deeper in the MS–HCP profiling was found to be incompatible with correct AGA detection in last purification intermediate and DS, further suggesting a hitchhiking behavior of AGA. In silico surface characterization of AGA also supports this hypothesis. Finally, the combined support of HCP ELISA results and MS allowed process optimization and removal of this copurifying HCP.<br />During monoclonal antibody 1 development, unexpected results generated with host cell protein (HCP) Enzyme‐Linked Immunosorbent Assay (ELISA) kit triggered an investigation which led to the identification of a copurifying HCP called N‐(4)‐(β‐acetylglucosaminyl)‐l‐asparaginase by liquid chromatography–tandem mass spectrometry (LC‐MS/MS). To mitigate the risk and improve the HCP clearance, a multidisciplinary approach was successfully applied including product and patient risk evaluation, in silico HCP surface characterization, and in‐depth understanding of this HCP behavior during downstream purification process.
- Subjects :
- 0106 biological sciences
0301 basic medicine
Glycan
host cell proteins
medicine.drug_class
Stability study
In silico
N‐(4)‐(β‐acetylglucosaminyl)‐ l‐asparaginase
Bioengineering
Enzyme-Linked Immunosorbent Assay
Monoclonal antibody
01 natural sciences
Applied Microbiology and Biotechnology
Article
HCP identification and quantitation by LC–MS/MS
L asparaginase
03 medical and health sciences
ARTICLES
Tandem Mass Spectrometry
010608 biotechnology
medicine
Asparaginase
hitchhiking behavior
Glucosamine
biology
Bioprocess Engineering and Supporting Technologies
Chemistry
Immunogenicity
Antibodies, Monoclonal
Proteins
risk assessment
Recombinant Proteins
030104 developmental biology
Biochemistry
biology.protein
HCP ELISA assay
Immunoglobulin G1
Biotechnology
Chromatography, Liquid
Subjects
Details
- ISSN :
- 10970290
- Volume :
- 117
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- Biotechnology and bioengineering
- Accession number :
- edsair.doi.dedup.....2f1b5afb8efee942fece4375b05affbf